ArticleBMC urology2026
Assessment of aminoglycosides and β-lactam resistance genes among uropathogens; a prospective-cross sectional study.
Article in BMC urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infections (UTIs) represent a major public health challenge worldwide, accounting for millions of outpatient consultations and substantial healthcare expenditure annually. In this prospective cross-sectional investigation conducted from February 2019 to January 2020 at a tertiary-care hospital in Islamabad, Pakistan, we examined the etiological agents of UTI, their antimicrobial susceptibility profiles, and the occurrence of the aminoglycoside resistance genes aac(6’)-Ib-cr and the β-lactam resistance genes blaTEM among 503 patients with suspected UTI. Culture-confirmed UTI was established in 127 patients (25.2%; 95% CI 21.5–29.3%), with markedly higher prevalence in females (33.6%) than males (16.8%; P < 0.001). Of these, 16 (12.6%) yielded polymicrobial growth. Gram-negative bacilli predominated (110/127 isolates, 86.6%), led by Escherichia coli (91/127, 71.7%), followed by Klebsiella spp. (9/127, 7.1%), Proteus spp. (6/127, 4.7%), and Pseudomonas spp. (4/127, 3.1%). Among Gram-negative isolates, susceptibility was highest to cefepime (75.8%) and cefoxitin (68.1%), whereas resistance exceeded 65% against gentamicin, ampicillin, ceftriaxone, and ciprofloxacin, with 68.1% classified as multidrug-resistant. Gram-positive isolates retained full susceptibility to imipenem and vancomycin. These findings underscore the urgent requirement for routine culture-guided therapy, enhanced antimicrobial stewardship, and continuous local surveillance to mitigate the emergence of untreatable uropathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.